An FDA advisory panel votes against recommending a new diabetes drug being developed by...

|By:, SA News Editor

An FDA advisory panel votes against recommending a new diabetes drug being developed by AstraZeneca (AZN) and Bristol-Myers (BMY), questioning whether there's sufficient efficacy and safety data to support the drug's approval. AstraZeneca -0.7% in London.